pharma · Osteoarthritis of the Knee
CellSeed Europe
CellSeed Europe Ltd
CellSeed Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Osteoarthritis of the Knee. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to t
GB HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- GB
- Programs
- 1
- Drugs
- 1
- Patents
- 0
CLS2901C (human [allogeneic] chondrocyte sheets)
Phase 3 · mab · Osteoarthritis of the Knee
CLS2901C (human [allogeneic] chondrocyte sheets) for Osteoarthritis of the Knee is a Phase 3 program (mab) at CellSeed Europe Ltd with 1 ClinicalTrials.gov record(s).
Internal code CLS2901-OAK-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CellSeed Europe Ltd
- Phase
- Phase 3
- Modality
- mab
- Indication
- Osteoarthritis of the Knee
- Status
- active
- Trials
- 1